WX-037

Compound Class	Small molecule PI3K inhibitor
Indication	Solid tumours, various cancers
Target	phosphatidylinositol-3-kinase/proteine-kinase (PI3K)
Mode of Action	The phosphatidylinositol-3-kinase/protein-kinase-B signalling pathway – PI3K in short – sends a “growth” signal to the nucleus of a tumour cell. It has been shown that abnormal mutations of the PI3K signalling pathway are present in most types of cancer. Identifying an inhibitor for the PI3K signalling pathway is thus of therapeutic interest.
Development Status	WILEX began the GMP (good manufacturing practice) synthesis and development and completed the first toxicity studies of WX-037. In February 2012 WILEX announced that it had been granted funding of up to EUR 2.6 million from the German Federal Ministry of Education and Research (BMBF) for the pre-clinical and clinical development of WX-037.
History	The PI3K inhibitor project was acquired from UCB at the beginning of 2009.

Seite gelesen: 1923 | Heute: 2